Grace Cherry, RN, MSN, NP, discusses recent advances in melanoma.
Grace Cherry, RN, MSN, NP, Melanoma Program, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses recent advances in melanoma.
Significant progress has been made in the treatment landscape of melanoma, says Cherry. Moreover, ongoing research suggests that certain combination therapies can re-induce an immune response in patients who progress on PD-1 inhibitors.
Moreover, on July 30, 2020, the FDA approved atezolizumab (Tecentriq) in combination with cobimetinib (Cotellic) and vemurafenib (Zelboraf) for patients with BRAF V600–mutation positive advanced melanoma based on findings from the phase 3 IMspire150 trial.
This is a valuable addition to the armamentarium, Cherry concludes.